Skip to main content
Premium Trial:

Request an Annual Quote

MDxHealth Inks Prostate Cancer Test Coverage Deal With Priority Health

NEW YORK (GenomeWeb) – MDxHealth today announced that its ConfirmMDx test for prostate cancer will now be covered by Michigan-based health plan Priority Health for all of its nearly 720,000 members.

Additional terms of the deal were not disclosed.

ConfirmMDx for Prostate Cancer detects the methylation status of biomarkers associated with the cancer development process, identifying patients who many not need a repeat biopsy following a negative result. Earlier this year, the test was included in the US 2016 National Comprehensive Cancer Network (NCCN) Guidelines for prostate cancer screening.

"With the recent inclusion of ConfirmMDx in the NCCN clinical guidelines, we are gaining more momentum with commercial payors," CEO Jan Groen said in a statement. "Our coverage for ConfirmMDx continues to grow, and the test is now covered by policies serving more than 50 percent of US at-risk males between the age of 50 and 74."

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.